General information about company

Standalone

Scrip code*	540679
NSE Symbol*	HALEOSLABS
MSEI Symbol*	NOTLISTED
ISIN*	INE320X01016
Name of company	Haleos Labs Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2026
Date of end of financial year	31-03-2027
Date of board meeting when results were approved	05-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	01-08-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	Bulk Drugs / API's
Start date and time of board meeting	05-08-2026 12:30
End date and time of board meeting	05-08-2026 13:45
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No	No default

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2026	01-04-2026
Date of end of reporting period		30-06-2026	30-06-2026
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	**Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.**		
1	**Income**		
	Revenue from operations	6782.97	6782.97
	Other income	45.61	45.61
	Total income	**6828.58**	**6828.58**
2	**Expenses**		
(a)	Cost of materials consumed	3728.42	3728.42
(b)	Purchases of stock-in-trade	-783.22	-783.22
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	1324.63	1324.63
(e)	Finance costs	181.33	181.33
(f)	Depreciation, depletion and amortisation expense	301.25	301.25
(g)	**Other Expenses**		
1	Manufacturing Expenses	1190	1190
2	Other Expenses	358.58	358.58
	Total other expenses	**1548.58**	**1548.58**
	Total expenses	**6300.99**	**6300.99**
3	**Total profit before exceptional items and tax**	**527.59**	**527.59**
4	Exceptional items	0	0
5	**Total profit before tax**	**527.59**	**527.59**
6	**Tax expense**		
7	Current tax	160	160
8	Deferred tax	43.81	43.81
9	**Total tax expenses**	**203.81**	**203.81**
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	**Net Profit Loss for the period from continuing operations**	**323.78**	**323.78**
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	**Net profit (loss) from discontinued operation after tax**	**0**	**0**
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	**Total profit (loss) for period**	**323.78**	**323.78**
17	Other comprehensive income net of taxes	1.95	1.95
18	**Total Comprehensive Income for the period**	**325.73**	**325.73**
19	**Total profit or loss, attributable to**		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	**Total Comprehensive income for the period attributable to**		
	Comprehensive income for the period attributable to owners of parent		

	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	**Details of equity share capital**			
	Paid-up equity share capital	302.33	302.33	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve			
23	**Earnings per share**			
i	**Earnings per equity share for continuing operations**			
	Basic earnings (loss) per share from continuing operations	10.71	10.71	
	Diluted earnings (loss) per share from continuing operations	10.71	10.71	
ii	**Earnings per equity share for discontinued operations**			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	**Earnings per equity share (for continuing and discontinued operations)**			
	Basic earnings (loss) per share from continuing and discontinued operations	10.71	10.71	
	Diluted earnings (loss) per share from continuing and discontinued operations	10.71	10.71	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	**Disclosure of notes on financial results**	**Textual Information(4)**		

Text Block	
Textual Information(4)	1. The above standalone Financial Results have been reviewed and recomended by the Audit Committee on 05th August, 2026 and have been approved by the Board of Directors at its meeting held on 05th August, 2026.The statutory auditors of the Company have carried out limited review of Standalone financial results for the quarter ended 30th June, 2026 and expressed unmodified opinion thereon. 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3 The figures for quarter ended 31st March, 2026 are balancing figures between audited figures of the full financial year ended 31st March, 2026 and the published year to date figures upto third quarter ended 31 st December, 2025, which were subjected to limited review by the auditors. 4 The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS1 08. 5 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification

Other Comprehensive Income

	Date of start of reporting period	01-04-2026	01-04-2026
	Date of end of reporting period	30-06-2026	30-06-2026
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss	-2.75	-2.75
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	0.80	0.80
5	Total Other comprehensive income	1.95	1.95

General information about company

Consolidated

Scrip code*	540679
NSE Symbol*	HALEOSLABS
MSEI Symbol*	NOTLISTED
ISIN*	INE320X01016
Name of company	Haleos Labs Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2026
Date of end of financial year	31-03-2027
Date of board meeting when results were approved	05-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	01-08-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	Bulk Drugs / API's
Start date and time of board meeting	05-08-2026 12:30
End date and time of board meeting	05-08-2026 13:45
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2026	01-04-2026
Date of end of reporting period		30-06-2026	30-06-2026
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
Part I	**Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.**		
1	**Income**		
	Revenue from operations	7294.23	7294.23
	Other income	46.33	46.33
	Total income	**7340.56**	**7340.56**
2	**Expenses**		
(a)	Cost of materials consumed	4013.81	4013.81
(b)	Purchases of stock-in-trade	-1368.21	-1368.21
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	1754.92	1754.92
(e)	Finance costs	189.96	189.96
(f)	Depreciation, depletion and amortisation expense	424.45	424.45
(g)	**Other Expenses**		
1	Manufacturing Expenses	1566.05	1566.05
2	Other Expenses	415.61	415.61
	Total other expenses	**1981.66**	**1981.66**
	Total expenses	**6996.59**	**6996.59**
3	**Total profit before exceptional items and tax**	**343.97**	**343.97**
4	Exceptional items	0	0
5	**Total profit before tax**	**343.97**	**343.97**
6	**Tax expense**		
7	Current tax	160	160
8	Deferred tax	-0.06	-0.06
9	**Total tax expenses**	**159.94**	**159.94**
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	**Net Profit Loss for the period from continuing operations**	**184.03**	**184.03**
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	**Net profit (loss) from discontinued operation after tax**	**0**	**0**
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	**Total profit (loss) for period**	**184.03**	**184.03**
17	Other comprehensive income net of taxes	4.28	4.28
18	**Total Comprehensive Income for the period**	**188.31**	**188.31**
19	**Total profit or loss, attributable to**		
	Profit or loss, attributable to owners of parent	264.66	264.66
	Total profit or loss, attributable to non-controlling interests	-80.63	-80.63
20	**Total Comprehensive income for the period attributable to**		
	Comprehensive income for the period attributable to owners of parent	268.01	268.01

	Total comprehensive income for the period attributable to owners of parent non-controlling interests	-79.7	-79.7	
21	**Details of equity share capital**			
	Paid-up equity share capital	302.33	302.33	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve			
23	**Earnings per share**			
i	**Earnings per equity share for continuing operations**			
	Basic earnings (loss) per share from continuing operations	8.75	8.75	
	Diluted earnings (loss) per share from continuing operations	8.75	8.75	
ii	**Earnings per equity share for discontinued operations**			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	**Earnings per equity share (for continuing and discontinued operations)**			
	Basic earnings (loss) per share from continuing and discontinued operations	8.75	8.75	
	Diluted earnings (loss) per share from continuing and discontinued operations	8.75	8.75	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	**Disclosure of notes on financial results**	**Textual Information(4)**		

Text Block	
Textual Information(4)	1. The above Consolidated Financial Results have been reviewed and recomended by the Audit Committee on 05th August, 2026 and have been approved by the Board of Directors at its meeting held on 05th August, 2026. The statutory auditors of the Company have carriedout limited review of Consolidated financial results for the quarter ended 30th June, 2026 and expressed unmodified opinion thereon. 2. The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 (lithe Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 3. The figures for quarter ended 31 st March , 2026 are balancing figures between audited figures of the full financial year ended 31 st March, 2026 and the published year to date figures upto third quarter ended 31st December, 2025, which were subjected to limited review by the statutory auditors 4. The Consolidated financial results are prepared by applying Ind AS-11 0 "Consolidated Financial Statements", includes financial results of Mahi Drugs Private Limited, a subsidiary. 5. The Consolidated entity is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108. 6. Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period' classification.

Other Comprehensive Income			
	Date of start of reporting period	01-04-2026	01-04-2026
	Date of end of reporting period	30-06-2026	30-06-2026
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Consolidated	Consolidated
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss	-5.90	-5.90
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	1.62	1.62
5	Total Other comprehensive income	4.28	4.28